Published in Breast Cancer Res Treat on May 01, 2003
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer (2008) 1.14
Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer (2008) 1.09
PPARγ maintains ERBB2-positive breast cancer stem cells. Oncogene (2013) 0.99
Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells. Postgrad Med J (2007) 0.99
Cytotoxic Activities against Breast Cancer Cells of Local Justicia gendarussa Crude Extracts. Evid Based Complement Alternat Med (2014) 0.96
Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br J Cancer (2006) 0.94
PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. J Cell Mol Med (2007) 0.93
Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol (2004) 0.92
Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy. Biochem J (2010) 0.92
Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion. Oncogene (2012) 0.91
PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells. PPAR Res (2011) 0.90
Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Mol Cancer (2008) 0.89
Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res (2008) 0.88
Amplified inhibition of stellate cell activation pathways by PPAR-γ, RAR and RXR agonists. PLoS One (2013) 0.86
Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. PPAR Res (2008) 0.85
15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev (2011) 0.85
All-trans retinoic acid (ATRA) downregulates MMP-9 by modulating its regulatory molecules. Cell Adh Migr (2010) 0.83
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling. Carcinogenesis (2015) 0.81
The Roles of Dietary PPARgamma Ligands for Metastasis in Colorectal Cancer. PPAR Res (2008) 0.80
15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss. PLoS One (2015) 0.80
Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ. PLoS One (2014) 0.80
PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion. PPAR Res (2008) 0.79
Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med (2014) 0.78
Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discov (2016) 0.78
All-trans-retinoic Acid Modulates the Plasticity and Inhibits the Motility of Breast Cancer Cells: ROLE OF NOTCH1 AND TRANSFORMING GROWTH FACTOR (TGFβ). J Biol Chem (2015) 0.77
PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes. PPAR Res (2008) 0.77
PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis. PPAR Res (2012) 0.77
MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX. Cytotechnology (2016) 0.77
Modification of MCF-10A cells with pioglitazone and serum-rich growth medium increases soluble factors in the conditioned medium, likely reducing BT-474 cell growth. Int J Mol Sci (2012) 0.77
Hepatic vitamin A preloading reduces colorectal cancer metastatic multiplicity in a mouse xenograft model. Nutr Cancer (2012) 0.77
PPARγ agonists target aromatase via both PGE2 and BRCA1. Cancer Prev Res (Phila) (2012) 0.76
Role of retinoids in the prevention and treatment of colorectal cancer. World J Gastrointest Oncol (2015) 0.76
Conjugated linoleic acid reduced metastasized LL2 tumors in mouse peritoneum. Virchows Arch (2006) 0.76
Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression. Oncotarget (2016) 0.76
All-trans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway. Br J Pharmacol (2015) 0.75
miRNA-10b sponge: An anti-breast cancer study in vitro. Oncol Rep (2016) 0.75
Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF‑7 cells by reducing FGF4 protein expression. Mol Med Rep (2016) 0.75
Expression of tissue inhibitor of matrix metalloproteinases-1 during aging in rat liver. World J Gastroenterol (2005) 0.75
A proline-type fullerene derivative inhibits adipogenesis by preventing PPARγ activation. Biochem Biophys Rep (2016) 0.75
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivation. Dev Biol (2000) 1.80
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Mucormycoses. Mycoses (2001) 1.70
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol (2008) 1.64
Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivator. Proc Natl Acad Sci U S A (1998) 1.41
Diagnosis and treatment of AL amyloidosis. Clin Nephrol (2000) 1.40
Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-alpha. Lancet (1993) 1.40
Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol (1995) 1.39
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Preliminary study on administration of high-titer lipid A antibody serum in sepsis and septic shock patients. Infection (1985) 1.35
msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation. Proc Natl Acad Sci U S A (1996) 1.27
Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol (2001) 1.20
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol (2007) 1.19
Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res (2001) 1.19
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol (2000) 1.17
MSG1 and its related protein MRG1 share a transcription activating domain. Gene (1997) 1.17
Number and location of AUUUA motifs: role in regulating transiently expressed RNAs. Blood (1994) 1.16
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol (1998) 1.14
Mössbauer effect in the ferredoxin of Euglena. Nature (1968) 1.09
Orbital metastases in breast cancer: report of two cases and review of the literature. J Cancer Res Clin Oncol (2004) 1.09
Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J (2010) 1.08
Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol (2000) 1.07
Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol (2001) 1.07
Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat (2002) 1.07
Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer (2003) 1.05
Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol (2009) 1.04
A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood (1996) 1.02
Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol (1997) 1.01
Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res (1999) 1.01
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol (2008) 1.01
Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol (2000) 1.00
ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers (2004) 0.96
Genetic variability in envelope-associated protein genes of closely related group A strains of respiratory syncytial virus. Virus Res (1999) 0.96
Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs (1999) 0.95
A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations? Eur J Cancer (2011) 0.94
Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol (2014) 0.93
Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. Int J Oncol (1999) 0.92
Effects of long-term administration of vitamin D3 analogs to mice. J Endocrinol (2000) 0.92
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs (2000) 0.92
Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cells. Exp Cell Res (1998) 0.91
Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Arch A Pathol Anat Histol (1982) 0.91
Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci (2001) 0.90
CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer (2001) 0.90
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anticancer Drugs (2001) 0.90
Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs (1999) 0.90
Disseminated mucormycosis caused by Absidia corymbifera leading to cerebral vasculitis. Infection (2000) 0.88
[Ptosis and ophthalmoplegia as predominant signs of multiple myeloma]. Dtsch Med Wochenschr (2004) 0.87
Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica (2001) 0.87
An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol (2013) 0.87
Dose-intensified weekly paclitaxel induces multiple nail disorders. Ann Oncol (1998) 0.86
Preadipocytes stimulate breast cancer cell growth. Nutr Cancer (1998) 0.86
The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res (2007) 0.86
Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leuk Res (1995) 0.86
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Res Treat (2012) 0.86
Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol (1990) 0.86
Metastatic breast cancer: are we treating the same patients as in the past? Ann Oncol (2013) 0.85
Light-dependent ethylene production by isolated chloroplasts. FEBS Lett (1974) 0.85
Early events of metastasis in the microcirculation involve changes in gene expression of cancer cells. Tracking mRNA levels of metastasizing cancer cells in the chick embryo chorioallantoic membrane. Am J Pathol (1997) 0.85
Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer (2012) 0.85
Oxidant-induced lung injury in anticancer therapy. Eur J Med Res (1999) 0.85
Detection of HMGI-C in the peripheral blood of breast cancer patients. Eur J Cancer (2000) 0.85
Chemotherapy for breast cancer brain metastases. Onkologie (2002) 0.85
Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Ann Hematol (2001) 0.84
Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol (2002) 0.83
Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol (1993) 0.83
First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res (2009) 0.83
Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing. Int J Biol Markers (2004) 0.83
Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study. Semin Oncol (1991) 0.82
[Primary cerebral highly-malignant B-cell lymphoma of the Burkitt type]. Dtsch Med Wochenschr (1999) 0.82
Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res (2001) 0.82
19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood (1998) 0.82
Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Res Treat (2009) 0.82
Primary hepatic or splenic diffuse large B-cell lymphoma and hepatitis C virus infection: a non-fortuitous association? Ann Hematol (2000) 0.82
Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res (2007) 0.82
The comparability of quality of life scores. a multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. Eur J Cancer (2002) 0.82
Immunohistochemical detection of CD10 with monoclonal antibody 56C6 on paraffin sections. Am J Clin Pathol (1999) 0.81
Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate (1997) 0.81
Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann N Y Acad Sci (2000) 0.81
[In vitro resistance testing of tumors in relation to cytostatics. 2. Examinations with human malignomas]. Onkologie (1980) 0.80
Alterations of differentiation, clonal proliferation, cell cycle progression and bcl-2 expression in RAR alpha-altered sublines of HL-60. Leukemia (1997) 0.80
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol (2005) 0.80
Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells. Biochem Biophys Res Commun (1999) 0.80
PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res (2005) 0.80
1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia. Leuk Res (1994) 0.80
Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol (2001) 0.80
Colitis associated with docetaxel-based chemotherapy. Lancet (2000) 0.80
Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. Br J Cancer (2000) 0.80
Clinical value of bisphosphonates in cancer therapy. Anticancer Res (2007) 0.80
Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria. Ann Hematol (2000) 0.79
Subacute encephalopathy after combination chemotherapy including moderate-dose methotrexate in a patient with gastric cancer. Anticancer Drugs (1999) 0.79
Myeloid differentiation mediated through retinoic acid receptor/retinoic X receptor (RXR) not RXR/RXR pathway. Blood (1994) 0.79
Interferon-alpha therapy for chronic myeloid leukemia during pregnancy. Am J Hematol (2006) 0.79
Feasibility of dose-intensified paclitaxel after chemotherapy-induced renal insufficiency in a patient with renal transplantation. Eur J Cancer (1999) 0.79